4.2 Article

Peripheral neuropathies during biologic therapies

期刊

MODERN RHEUMATOLOGY
卷 26, 期 2, 页码 288-293

出版社

SPRINGER
DOI: 10.3109/14397595.2013.859770

关键词

Biological agents; Peripheral neuropathy

资金

  1. Mitsubishi Tanabe Pharmaceutical Company (Osaka, Japan)
  2. Teijin Pharma Limited (Osaka, Japan)
  3. AstraZeneca K.K. (Osaka, Japan)

向作者/读者索取更多资源

Peripheral neuropathies should be recognized as the adverse effects of biological agents, especially anti-TNF agents. However, no solid clinical databases for biological agent-associated peripheral neuropathies (BAPN) have been established in Japan. Here we report two cases of peripheral neuropathy associated with anti-TNF agents. One was peroneal motor neuropathy. The other case was chronic inflammatory demyelinating polyradiculoneuropathy. In addition, we summarize the previous reports on BAPN and discuss their prevalence rate, pathogenesis and management.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据